Uncertainty, Coping Strategies Common Among Patients With AML, High-Risk MDS
February 2nd 2024Patients with comorbid acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) expressed a desire to discuss treatment options and maintain normalcy; they were not willing to have conversations involving their prognosis and future.
Read More
Real-World Data Show Suboptimal Efficacy With AZA in Treatment-Naïve High-Risk MDS
January 26th 2024Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).
Read More
Study Highlights Need for Additional Caregiver Support in Higher-Risk MDS
January 23rd 2024The study, which pulled self-reported data from online bulletin boards across the US, Canada, and the United Kingdom in 2020, found that the degree of burden varied based on patient disease stage, among other factors.
Read More
Online Workshop Reveals Patient, Future Research Priorities in MDS
January 17th 2024Myelodysplastic syndrome is an extremely heterogeneous disease, and there is no definitive cure, so these investigators wanted a better understanding of patients’ priorities regarding their care, quality of life, and communication with the care team.
Read More
Data Show Trend Toward Improved Persistence After 6 Months With Oral MDS Regimen
December 20th 2023The authors concluded that the data support consideration of the oral regimen of decitabine and cedazuridine to reduce the treatment burden associated with intraveous or subcutaneous hypomethylating agents in patients with myelodysplastic syndromes (MDS).
Read More
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More
Allogeneic HCT Provides OS Benefit Independent of TP53 Allelic Status in MDS
November 27th 2023Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status.
Read More
Authors Support Trials of Triplet Therapy in Higher-Risk MDS
November 9th 2023Given the likelihood of MDS to progress to acute myeloid leukemia (AML), the authors state, “There are certain settings where ‘AML-like’ therapies are appropriate in MDS, particularly given our evolving understanding of the overlapping biology of these malignancies.”
Read More
Higher Leptin Levels, Body Fat Linked to MDS in Study
October 20th 2023The authors discussed a polymorphism of the LEP gene associated not only with cancer, but also with chronic diseases including obesity and diabetes, offering them a reason to look into the relationship between LEP and myelodysplastic syndrome (MDS).
Read More
Updates Are Driving the Field of MDS Forward, but Changes Still Needed
September 25th 2023In just the last 2 years there have been updates in classification, risk assessment, and response criteria in myelodysplastic syndromes (MDS), but additional efforts are needed to improve these, and there remains a need for better therapies.
Read More
Review: Venetoclax Plus HMAs Offer “Moderate” Benefit in AML/MDS After Relapse Post Transplant
August 22nd 2023There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation.
Read More
Small Study Shows Utility of ctDNA for Monitoring Treatment Response, Evolution of MDS, AML
August 9th 2023Investigators from China used circulating tumor DNA testing alongside bone marrow assessments to evaluate patients' pretreatment and posttreatment disease levels and to track the course of the disease.
Read More
Gilead Discontinues Phase 3 ENHANCE Trial of Magrolimab/Azacitidine in Higher-Risk MDS
August 7th 2023The phase 3 ENHANCE trial evaluating the first-line combination of magrolimab and azacitidine vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome has been discontinued due to futility at a planned analysis.
Read More
Annual Clinical Update on MDS Sees Hope in Precision Medicine, Use of Oral Therapy
July 29th 2023An overview of the 2023 recommendations on myelodysplastic syndromes by Guillermo Garcia-Mareno, MD, of MD Anderson Cancer Center, appears in the August issue of the American Journal of Hematology.
Read More
Common CVD Biomarkers May Hold Prognostic Value in MDS, Study Finds
July 19th 2023The findings suggest that circulating N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15, both soluble biomarkers of cardiovascular disease (CVD), may be indicators of the course of myelodysplastic syndromes (MDS) and outcomes.
Read More
Study Explores Risk Factors for Therapy-Related MDS, AML Following HCT for Multiple Myeloma
July 14th 2023The occurrence of treatment-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after autologous hematopoietic cell transplantation (HCT) for multiple myeloma was associated with aggressive disease characteristics and poor outcomes.
Read More